Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Net Income (2020 - 2025)

Historic Net Income for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' Net Income rose 2311.31% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 388.48%. This contributed to the annual value of -$149.1 million for FY2024, which is 4608.11% down from last year.
  • Per Caribou Biosciences' latest filing, its Net Income stood at -$29.4 million for Q3 2025, which was up 2311.31% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Net Income registered a high of -$13.2 million during Q1 2021, and its lowest value of -$47.6 million during Q2 2025.
  • Over the past 5 years, Caribou Biosciences' median Net Income value was -$30.6 million (recorded in 2022), while the average stood at -$30.3 million.
  • In the last 5 years, Caribou Biosciences' Net Income crashed by 66447.65% in 2021 and then surged by 4485.81% in 2023.
  • Caribou Biosciences' Net Income (Quarter) stood at -$18.5 million in 2021, then plummeted by 65.47% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 24.37% to -$29.4 million in 2025.
  • Its last three reported values are -$29.4 million in Q3 2025, -$47.6 million for Q2 2025, and -$42.9 million during Q1 2025.